Pulmatrix Initiates European Pilot Bioequivalence Study of PUR0200 for COPD
Pulmatrix, Inc. reported that enrollment is underway in the company’s European pilot bioequivalence study of PUR0200, a proprietary iSPERSE™ (Inhaled Small Particles Easily Respirable and Emitted) engineered dry powder formulation of a marketed long acting muscarinic antagonist bronchodilator for the treatment of chronic obstructive pulmonary disease (COPD). [Pulmatrix, Inc.] Press Release
Bonnie J. Addario Lung Cancer Foundation Launches Second Phase of $180,000 Clinical Trial Innovation Prize
The Bonnie J. Addario Lung Cancer Foundation launched the second phase of the Clinical Trial Innovation Prize, a unique crowdsourcing challenge that identifies innovative ways to increase cancer patient enrollment in clinical trials. The goal of the challenge is to produce breakthroughs that will double the patient accrual rate of clinical trials evaluating interventions in the diagnosis and treatment of all cancers. [Bonnie J. Addario Lung Cancer Foundation (PR Newswire Association LLC)]
Press Release
Recruit Top Talent:
Reach more than 60,000 potential candidates by posting
your organization’s career opportunities on the Connexon Creative Job Board at no cost.
Have we missed an important article or publication in Pulmonary Cell News? Click here to submit!